Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells
- Anticancer Res. 2022 May;42(5):2487-2493. doi: 10.21873/anticanres.15727.
- 1. Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei, Taiwan, R.O.C.
- 2. Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan, R.O.C.
- 3. Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei, Taiwan, R.O.C.; [email protected].
- 4. Institute of Biomedical Sciences, Mackay Medical College, New Taipei City, Taiwan, R.O.C.
- 5. Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C.
Background/aim: Expression of sterol regulatory element-binding protein 1 (SREBP1) is upregulated in Thyroid Cancer and associated with shorter disease-specific survival. The molecular regulatory mechanisms governing SREBP1 over-expression in Thyroid Cancer are still unclear.
Materials and methods: Thyroid Cancer cell lines BHT-101 (with the BRAF V600E mutation) and FTC-131 (wild-type for BRAF) were treated with specific inhibitors. The expression of SREBP1 was determined at the mRNA level using quantitative Real-Time PCR and at the protein level using immunoblotting.
Results: Lenvatinib and a MEK Inhibitor, selumetinib, suppressed SREBP1 expression in BHT-101 but not FTC-133 cells. Olitigaltin, a Galectin-3 Inhibitor, decreased SREBP1 expression in a time- and dose-dependent manner in both cells. MK2206, an allosteric Akt Inhibitor, did not change SREBP1 expression in either cell line.
Conclusion: The Galectin-3 Inhibitor attenuates SREBP1 expression in Thyroid Cancer cells, likely independent of Akt phosphorylation. Lenvatinib and selumetinib decreases SREBP1 expression in the BRAF-mutant cell line BHT-101.
-
Cat. No.Product NameDescriptionTargetResearch Area
-